Massachusetts Financial Services Co. MA Invests $7.75 Million in Haleon PLC Sponsored ADR $HLN

Massachusetts Financial Services Co. MA bought a new position in Haleon PLC Sponsored ADR (NYSE:HLN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 766,999 shares of the company’s stock, valued at approximately $7,754,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. First Eagle Investment Management LLC lifted its holdings in shares of Haleon by 9.8% during the third quarter. First Eagle Investment Management LLC now owns 3,056,951 shares of the company’s stock valued at $27,421,000 after purchasing an additional 273,044 shares in the last quarter. JTC Employer Solutions Trustee Ltd lifted its holdings in shares of Haleon by 120.7% during the third quarter. JTC Employer Solutions Trustee Ltd now owns 712,229 shares of the company’s stock valued at $6,392,000 after purchasing an additional 389,467 shares in the last quarter. Arlington Partners LLC lifted its holdings in shares of Haleon by 128.0% during the third quarter. Arlington Partners LLC now owns 508,886 shares of the company’s stock valued at $4,565,000 after purchasing an additional 285,692 shares in the last quarter. Archford Capital Strategies LLC bought a new position in shares of Haleon during the third quarter valued at $2,149,000. Finally, Cidel Asset Management Inc. bought a new position in shares of Haleon during the third quarter valued at $4,043,000. 6.67% of the stock is owned by institutional investors.

Haleon Stock Performance

Shares of HLN opened at $9.59 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. The business has a 50-day simple moving average of $10.38 and a two-hundred day simple moving average of $9.93. The stock has a market cap of $42.74 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 2.05 and a beta of 0.26. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The company had revenue of $3.65 billion during the quarter. On average, analysts expect that Haleon PLC Sponsored ADR will post 0.43 EPS for the current year.

Haleon Dividend Announcement

The firm also recently announced a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be given a dividend of $0.1307 per share. The ex-dividend date is Friday, April 10th. This represents a dividend yield of 266.0%. Haleon’s dividend payout ratio (DPR) is currently 64.10%.

Analyst Ratings Changes

HLN has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft downgraded Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Finally, Argus raised Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.